CRISPR Therapeutics' drug pipeline revolves around ... published Dec. 20 that it had parted ways with its head of R&D, Tony Ho. Even with the dramatic pullback across the last year of trading ...

Aug. 01, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the appointment ...

Prior to CRISPR Therapeutics, Dr. Ho was SVP and Head ... is the solid cornerstone of Qihan's product innovation," said Dr. Tony Ho. "I am delighted to join Qihan's Board of Directors, and my ...

Dr. Tony Ho is CRISPR's Head of Research and Development ... shows evidence of durable editing in bone marrow. Source: CRISPR Therapeutics corporate presentation August 2021.

Heralding a new era in gene-editing medicines, Crispr is innovating a deep portfolio of therapeutics servicing ... that I was disappointed to see Dr. Tony Ho (i.e., the former Head of Research ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%.Jun-25 30 calls and Oct-25 40 calls are the ...

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage ...

05. Scribe Therapeutics has laid off just under 20% of its staff, the company confirmed to STAT on Wednesday, joining a slate of CRISPR gene editing companies to cut staff amid a prolonged ...

CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...

Crispr Therapeutics on Tuesday said that Phuong Khanh Morrow was resigning as the gene-editing company’s chief medical officer, a move that takes hold on Jan. 26. The resignation was “not the ...